electroCore, Inc. (ECOR)
| Market Cap | 76.82M +101.1% |
| Revenue (ttm) | 36.97M +33.5% |
| Net Income | -14.77M |
| EPS | -1.66 |
| Shares Out | 9.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 232,030 |
| Open | 7.19 |
| Previous Close | 7.23 |
| Day's Range | 7.19 - 8.59 |
| 52-Week Range | 4.41 - 12.70 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 19.17 (+125.0%) |
| Earnings Date | Nov 4, 2026 |
About ECOR
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer... [Read more]
Financial Performance
In 2025, electroCore's revenue was $32.03 million, an increase of 27.20% compared to the previous year's $25.18 million. Losses were -$13.97 million, 17.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ECOR stock is "Strong Buy." The 12-month stock price target is $19.17, which is an increase of 125.00% from the latest price.
News
electroCore sees FY26 revenue $39M-$42M, consensus $41.92M
The company said, “The Company is revising its full-year 2026 revenue outlook to a range of $39 million to $42 million, from its prior guidance of greater than 30% revenue…
electroCore sees FY27 revenue up 30%-40%
The company said, “The Company is also introducing preliminary 2027 revenue guidance of 30% to 40% revenue growth over full year 2026 revenue and expects to achieve its first quarter…
electroCore reports Q3 EPS (13c) vs. (40c) last year
Reports Q3 revenue $9.69M, consensus $10.93M. “This quarter reflects the early stages of a more efficient commercial organization,” said Joshua Lev, Co-Chief Executive Officer, President, and Chief Fi...
electroCore Earnings Call Transcript: Q3 2026
Q3 delivered record sales of $9.7M, 88.5% gross margin and a record-low $0.7M adjusted EBITDA loss. FY2026 revenue guidance was lowered to $39M-$42M as expected acceleration shifted to 2027, when growth of 30%-40% and positive adjusted EBITDA by year-end are targeted.
electroCore Earnings release: Q3 2026
electroCore released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
electroCore Quarterly report: Q3 2026
electroCore has published its Q3 2026 quarterly earnings report on November 4, 2026.
electroCore Announces Third Quarter 2026 Financial Results
Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss im...
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial re...
electroCore Transcript: Planet MicroCap Showcase: Toronto 2026
Revenue reached $19M in 1H2026, with gross margins in the mid-to-high 80s and a target of adjusted EBITDA positivity in 2H2027. Growth priorities include federal-market expansion and advancing Quell, including its CIPN 510(k) filing.
electroCore submits 510 premarket notification to FDA for Quell
electroCore (ECOR) announced that it has submitted a 510 premarket notification to the FDA seeking 510(k) clearance for its Quell wearable neuromodulation platform for the treatment of chronic chemoth...
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ROCKAWAY, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), (“electroCore” or the “Company”), a bioelectronic technology company, today announced that it has submitted a 510(k)...
fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning
ROCKAWAY, N.J.,, Oct. 27, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced fi...
electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub
ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet...
electroCore to Participate at H.C. Wainwright Global Investment Conference
ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in...
electroCore appoints Joshua Lev, Mike Fox as co-CEOs
electroCore (ECOR) announced that it has appointed Joshua Lev and Mike Fox as co-CEO and members of the board of directors, effective September 8. Lev has been with the company…
electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
ROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation t...
electroCore Transcript: AGM 2026
The meeting confirmed a quorum, elected three directors for new terms, ratified the independent auditors for 2026, and approved executive compensation on an advisory basis. No shareholder proposals were presented. Final voting results will be filed with the SEC.
electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience Recognition highlights Truvaga's combin...
electroCore raises FY26 revenue view to up over 30% from up 30%
The company said, “The Company is raising its full-year 2026 revenue guidance to greater than 30% annual growth over full-year 2025 and expects to achieve positive Adjusted EBITDA in the…
electroCore reports Q2 EPS (33c) vs. (44c) last year
Reports Q2 revenue $8.18M, consensus $9.49M. “This quarter marked a new era for our company as we implemented significant changes across our commercial organization to better position us for long-term...
electroCore Earnings Call Transcript: Q2 2026
Q2 2026 revenue rose 28% year-over-year to $9.5 million, driven by VA and Quell growth. Guidance was raised to over 30% annual revenue growth, with improved profitability and a path to positive adjusted EBITDA by Q3 2027. Major sales force expansion and operational changes support future growth.
electroCore Quarterly report: Q2 2026
electroCore has published its Q2 2026 quarterly earnings report on August 6, 2026.
electroCore Earnings release: Q2 2026
electroCore released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
electroCore Announces Second Quarter 2026 Financial Results
Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss impr...
electroCore could report ‘conservative’ guidance with Q2, says H.C. Wainwright
ElectroCore (ECOR) enters its Q2 report with expectations for conservative guidance, strong gross margins, and accelerating second-half growth, while investors focus on improving VA utilization and th...